COST-EFFECTIVENESS ANALYSIS OF THE EASL 2009 CLINICAL PRACTICE GUIDELINES FOR MANAGEMENT OF CHRONIC HEPATITIS B IN FRANCE, ITALY, PORTUGAL, SPAIN, TURKEY AND THE UNITED KINGDOM

被引：1
|
作者：
Vanness, D. J. [1 ]
Singfield, C. [2 ]
Joseph, I. A. [3 ]
van Nooten, F. [5 ]
Agarwal, K. [4 ]
Buti, M. [6 ]
Cakaloglu, Y. [7 ]
Marinho, R. T. [8 ]
Zarski, J. P. [9 ]
Hartz, S. [5 ]
De Cock, E. [10 ]
Revankar, N. [3 ]
Raluy, M. [10 ]
Hutt, E. [2 ]
机构：
[1] United BioSource Corp, Madison, WI USA
[2] Gilead Sci, Uxbridge, Middx, England
[3] United BioSource Corp, Lexington, MA USA
[4] Kings Coll Hosp London, London, England
[5] United BioSource Corp, London, England
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Mem Hosp, Istanbul, Turkey
[8] Hosp Santa Maria, Lisbon, Portugal
[9] CHU Grenoble, F-38043 Grenoble, France
[10] United BioSource Corp, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 52卷
关键词：
D O I：
10.1016/S0168-8278(10)61030-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S398 / S398
页数：1
相关论文
共 26 条
  • [1] EASL Clinical Practice Guidelines: Management of chronic hepatitis B
    Marcellin, Patrick
    Dusheiko, Geoffrey
    Zoulim, Fabien
    Esteban, Rafael
    Hadziyannis, Stefanos
    Lampertico, Pietro
    Manns, Michael
    Shouval, Daniel
    Yurdaydin, Cihan
    JOURNAL OF HEPATOLOGY, 2009, 50 (02) : 227 - 242
  • [2] Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
    Svedbom, A.
    Hadji, P.
    Hernlund, E.
    Thoren, R.
    McCloskey, E.
    Stad, R.
    Stollenwerk, B.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 (09) : 1745 - 1754
  • [3] Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
    A. Svedbom
    P. Hadji
    E. Hernlund
    R. Thoren
    E. McCloskey
    R. Stad
    B. Stollenwerk
    Osteoporosis International, 2019, 30 : 1745 - 1754
  • [4] Hepatitis B management costs in France, Italy, Spain, and the United Kingdom
    Brown, RE
    De Cock, E
    Colin, X
    Antoñanzas, F
    Iloeje, UH
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2004, 38 (10) : S169 - S174
  • [5] EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
    Papatheodoridis, George
    Buti, Maria
    Cornberg, Markus
    Janssen, Harry
    Mutimer, David
    Pol, Stanislas
    Raimondo, Giovanni
    JOURNAL OF HEPATOLOGY, 2012, 57 (01) : 167 - 185
  • [6] EASL clinical practice guidelines on the management of chronic hepatitis B: The need for liver biopsy
    Papatheodoridis, George V.
    Manolakopoulos, Spilios
    JOURNAL OF HEPATOLOGY, 2009, 51 (01) : 226 - 227
  • [7] Applicability of cost-effectiveness analysis to management of chronic hepatitis B
    Dan, Yock Young
    Lim, Seng Gee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (09) : 1357 - 1359
  • [8] EASL Clinical Practice Guidelines. Management of chronic hepatitis B European Association for the Study of the Liver
    European Association for the Study of the Liver
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 (6-7): : 539 - 554
  • [9] A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy
    Colombo, Giorgio L.
    Gaeta, Giovanni B.
    Vigano, Mauro
    Di Matteo, Sergio
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 37 - 46
  • [10] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection (vol 57, pg 167, 2012)
    Papatheodoridis, George
    JOURNAL OF HEPATOLOGY, 2013, 58 (01) : 201 - 201
123